{"abstract":"This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the following inventions embodied in the following patent applications, entitled \"CB1 receptor mediating compounds\":","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/04/19/2016-08985.html","cfr_references":[],"citation":"81 FR 22995","comment_url":null,"comments_close_on":"2016-05-04","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the Technology Advancement Office, The National Institute of Diabetes and Digestive and Kidney Diseases on or before May 4, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-08985","effective_on":null,"end_page":22995,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/04/19/2016-08985.xml","html_url":"https://www.federalregister.gov/documents/2016/04/19/2016-08985/prospective-grant-of-exclusive-license-development-of-the-cb1inos-series-of-compounds-as-a","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-08985?publication_date=2016-04-19","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-04-19/2016-08985/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":243,"last_updated":"2026-08-24 14:15:12 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-04-19/pdf/2016-08985.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-08985.pdf?1460983566","publication_date":"2016-04-19","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/04/19/2016-08985.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T21:16:31Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":22995,"subtype":null,"title":"Prospective Grant of Exclusive License: Development of the CB1/iNOS Series of Compounds as a Therapeutic To Treat System Sclerosis, Scleroderma, and Other Skin Fibrotic Diseases in Humans","toc_doc":"Development of the CB1/iNOS Series of Compounds as a Therapeutic to Treat System Sclerosis, Scleroderma, and Other Skin Fibrotic Diseases in Humans","toc_subject":"Exclusive Licenses:","topics":[],"type":"Notice","volume":81}